Skip to main content
SpringerLink
Log in

Antagonism of angiotensin 1–7 prevents the therapeutic effects of recombinant human ACE2

  • Original Article
  • Published:
Journal of Molecular Medicine Aims and scope Submit manuscript

Abstract

Activation of the angiotensin 1–7/Mas receptor (MasR) axis counteracts angiotensin II (Ang II)-mediated cardiovascular disease. Recombinant human angiotensin-converting enzyme 2 (rhACE2) generates Ang 1–7 from Ang II. We hypothesized that the therapeutic effects of rhACE2 are dependent on Ang 1–7 action. Wild type male C57BL/6 mice (10–12 weeks old) were infused with Ang II (1.5 mg/kg/d) and treated with rhACE2 (2 mg/kg/d). The Ang 1–7 antagonist, A779 (200 ng/kg/min), was administered to a parallel group of mice. rhACE2 prevented Ang II-induced hypertrophy and diastolic dysfunction while A779 prevented these beneficial effects and precipitated systolic dysfunction. rhACE2 effectively antagonized Ang II-mediated myocardial fibrosis which was dependent on the action of Ang 1–7. Myocardial oxidative stress and matrix metalloproteinase 2 activity was further increased by Ang 1–7 inhibition even in the presence of rhACE2. Activation of Akt and endothelial nitric oxide synthase (eNOS) by rhACE2 were suppressed by the antagonism of Ang 1–7 while the activation of pathological signaling pathways was maintained. Blocking Ang 1–7 action prevents the therapeutic effects of rhACE2 in the setting of elevated Ang II culminating in systolic dysfunction. These results highlight a key cardioprotective role of Ang 1–7, and increased Ang 1–7 action represents a potential therapeutic strategy for cardiovascular diseases.

Key messages

  • Activation of the renin–angiotensin system (RAS) plays a key pathogenic role in cardiovascular disease.

  • ACE2, a monocarboxypeptidase, negatively regulates pathological effects of Ang II.

  • Antagonizing Ang 1–7 prevents the therapeutic effects of recombinant human ACE2.

  • Our results highlight a key protective role of Ang 1–7 in cardiovascular disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, Loibner H, Wang XH, Penninger JM, Kassiri Z et al (2010) Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122:717–728

    Article  CAS  PubMed  Google Scholar 

  2. Mori J, Basu R, McLean BA, Das SK, Zhang L, Patel VB, Wagg CS, Kassiri Z, Lopaschuk GD, Oudit GY (2012) Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction. Circ Heart Fail 5:493–503

    Article  CAS  PubMed  Google Scholar 

  3. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ (2000) A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275:33238–33243

    Article  CAS  PubMed  Google Scholar 

  4. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R et al (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 87:E1–E9

    Article  CAS  PubMed  Google Scholar 

  5. Santos RA (2014) Angiotensin-(1–7). Hypertension 63:1138–1147

    Article  CAS  PubMed  Google Scholar 

  6. Passos-Silva DG, Verano-Braga T, Santos RA (2013) Angiotensin-(1–7): beyond the cardio-renal actions. Clin Sci (Lond) 124:443–456

    Article  CAS  Google Scholar 

  7. Patel VB, Bodiga S, Fan D, Das SK, Wang Z, Wang W, Basu R, Zhong J, Kassiri Z, Oudit GY (2012) Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1–7 in experimental heart failure in angiotensin-converting enzyme 2-null mice. Hypertension 59:1195–1203

    Article  CAS  PubMed  Google Scholar 

  8. Mercure C, Yogi A, Callera GE, Aranha AB, Bader M, Ferreira AJ, Santos RA, Walther T, Touyz RM, Reudelhuber TL (2008) Angiotensin(1–7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res 103:1319–1326

    Article  CAS  PubMed  Google Scholar 

  9. Wang W, Bodiga S, Das SK, Lo J, Patel V, Oudit GY (2012) Role of ACE2 in diastolic and systolic heart failure. Heart Fail Rev 17:683–691

    Article  CAS  PubMed  Google Scholar 

  10. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399:601–605

    Article  CAS  PubMed  Google Scholar 

  11. Dominici FP, Burghi V, Munoz MC, Giani JF (2014) Modulation of the action of insulin by angiotensin-(1–7). Clin Sci (Lond) 126:613–630

    Article  CAS  Google Scholar 

  12. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM (2007) Angiotensin-(1–7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49:185–192

    Article  CAS  PubMed  Google Scholar 

  13. Gomes ER, Lara AA, Almeida PW, Guimaraes D, Resende RR, Campagnole-Santos MJ, Bader M, Santos RA, Guatimosim S (2010) Angiotensin-(1–7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3′,5′-cyclic monophosphate-dependent pathway. Hypertension 55:153–160

    Article  CAS  PubMed  Google Scholar 

  14. Santos RA, Campagnole-Santos MJ, Baracho NC, Fontes MA, Silva LC, Neves LA, Oliveira DR, Caligiorne SM, Rodrigues AR, Gropen Junior C et al (1994) Characterization of a new angiotensin antagonist selective for angiotensin-(1–7): evidence that the actions of angiotensin-(1–7) are mediated by specific angiotensin receptors. Brain Res Bull 35:293–298

    Article  CAS  PubMed  Google Scholar 

  15. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M et al (2003) Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100:8258–8263

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Bodiga S, Zhong JC, Wang W, Basu R, Lo J, Liu GC, Guo D, Holland SM, Scholey JW, Penninger JM et al (2011) Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit. Cardiovasc Res 91:151–161

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Patel VB, Bodiga S, Basu R, Das SK, Wang W, Wang Z, Lo J, Grant MB, Zhong J, Kassiri Z et al (2012) Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ Res 110:1322–1335

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Putko BN, Wang Z, Lo J, Anderson T, Becher H, Dyck JR, Kassiri Z, Oudit GY, Alberta HI (2014) Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology. PLoS One 9, e99495. doi:10.1371/journal.pone.0099495

    Article  PubMed Central  PubMed  Google Scholar 

  19. Patel VB, Zhong JC, Fan D, Basu R, Morton JS, Parajuli N, McMurtry MS, Davidge ST, Kassiri Z, Oudit GY (2014) Angiotensin-converting enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodeling. Hypertension 64:157–164

    Article  CAS  PubMed  Google Scholar 

  20. Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu PP, Scholey JW, Penninger JM, Oudit GY (2009) Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail 2:446–455

    Article  CAS  PubMed  Google Scholar 

  21. Weber KT, Brilla CG (1991) Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83:1849–1865

    Article  CAS  PubMed  Google Scholar 

  22. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, Greenberg BH (2005) Angiotensin-(1–7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 289:H2356–H2363

    Article  CAS  PubMed  Google Scholar 

  23. Zhong J, Guo D, Chen CB, Wang W, Schuster M, Loibner H, Penninger JM, Scholey JW, Kassiri Z, Oudit GY (2011) Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 57:314–322

    Article  CAS  PubMed  Google Scholar 

  24. Uhal BD, Li X, Piasecki CC, Molina-Molina M (2012) Angiotensin signalling in pulmonary fibrosis. Int J Biochem Cell Biol 44:465–468

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW (1994) Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74:1141–1148

    Article  CAS  PubMed  Google Scholar 

  26. Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292:C82–C97

    Article  CAS  PubMed  Google Scholar 

  27. Sampaio WO, Henrique de Castro C, Santos RA, Schiffrin EL, Touyz RM (2007) Angiotensin-(1–7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 50:1093–1098

    Article  CAS  PubMed  Google Scholar 

  28. Khan SA, Skaf MW, Harrison RW, Lee K, Minhas KM, Kumar A, Fradley M, Shoukas AA, Berkowitz DE, Hare JM (2003) Nitric oxide regulation of myocardial contractility and calcium cycling: independent impact of neuronal and endothelial nitric oxide synthases. Circ Res 92:1322–1329

    Article  CAS  PubMed  Google Scholar 

  29. Takimoto E, Kass DA (2007) Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension 49:241–248

    Article  CAS  PubMed  Google Scholar 

  30. Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7:589–600

    Article  CAS  PubMed  Google Scholar 

  31. Mori J, Patel VB, Abo Alrob O, Basu R, Altamimi T, Desaulniers J, Wagg CS, Kassiri Z, Lopaschuk GD, Oudit GY (2014) Angiotensin 1–7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation. Circ Heart Fail 7:327–339

    Article  CAS  PubMed  Google Scholar 

  32. Mori J, Patel VB, Ramprasath T, Alrob OA, DesAulniers J, Scholey JW, Lopaschuk GD, Oudit GY (2014) Angiotensin 1–7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol Renal Physiol 306:F812–F821

    Article  CAS  PubMed  Google Scholar 

  33. Oudit GY, Penninger JM (2011) Recombinant human angiotensin-converting enzyme 2 as a new renin-angiotensin system peptidase for heart failure therapy. Curr Heart Fail Rep 8:176–183

    Article  CAS  PubMed  Google Scholar 

  34. Patel VB, Parajuli N, Oudit GY (2014) Role of angiotensin-converting enzyme 2 (ACE2) in diabetic cardiovascular complications. Clin Sci (Lond) 126:471–482

    Article  CAS  Google Scholar 

  35. Lo J, Patel VB, Wang Z, Levasseur J, Kaufman S, Penninger JM, Oudit GY (2013) Angiotensin-converting enzyme 2 antagonizes angiotensin II-induced pressor response and NADPH oxidase activation in Wistar-Kyoto rats and spontaneously hypertensive rats. Exp Physiol 98:109–122

    Article  CAS  PubMed  Google Scholar 

  36. Wysocki J, Ye M, Rodriguez E, Gonzalez-Pacheco FR, Barrios C, Evora K, Schuster M, Loibner H, Brosnihan KB, Ferrario CM et al (2010) Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 55:90–98

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Poglitsch M, Domenig O, Schwager C, Stranner S, Peball B, Janzek E, Wagner B, Jungwirth H, Loibner H, Schuster M (2012) Recombinant expression and characterization of human and murine ACE2: species-specific activation of the alternative renin-angiotensin-system. Int J Hypertens 2012:428950

    Article  PubMed Central  PubMed  Google Scholar 

  38. Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J, Krahenbuhl S (2013) Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects. Clin Pharmacokinet 52:783–792

    Article  CAS  PubMed  Google Scholar 

  39. Collister JP, Nahey DB (2010) Simultaneous administration of Ang(1–7) or A-779 does not affect the chronic hypertensive effects of angiotensin II in normal rats. J Renin Angiotensin Aldosterone Syst 11:99–102

    Article  CAS  PubMed  Google Scholar 

  40. Wang W, Patel VB, Parajuli N, Fan D, Basu R, Wang Z, Ramprasath T, Kassiri Z, Penninger JM, Oudit GY (2014) Heterozygote loss of ACE2 is sufficient to increase the susceptibility to heart disease. J Mol Med (Berl) 92:847–858

    Article  CAS  Google Scholar 

  41. Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, Loibner H, Janzek E, Schuster M, Penninger JM et al (2010) Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 59:529–538

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Santos SH, Giani JF, Burghi V, Miquet JG, Qadri F, Braga JF, Todiras M, Kotnik K, Alenina N, Dominici FP et al (2014) Oral administration of angiotensin-(1–7) ameliorates type 2 diabetes in rats. J Mol Med (Berl) 92:255–265

    Article  CAS  Google Scholar 

  43. Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G, Ketner EA, Majmudar M, Gabrielson K, Halushka MK et al (2008) Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 117:2626–2636

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Parajuli N, Patel VB, Wang W, Basu R, Oudit GY (2014) Loss of NOX2 (gp91phox) prevents oxidative stress and progression to advanced heart failure. Clin Sci (Lond) 127:331–340

    Article  CAS  Google Scholar 

  45. Dias-Peixoto MF, Santos RA, Gomes ER, Alves MN, Almeida PW, Greco L, Rosa M, Fauler B, Bader M, Alenina N et al (2008) Molecular mechanisms involved in the angiotensin-(1–7)/Mas signaling pathway in cardiomyocytes. Hypertension 52:542–548

    Article  CAS  PubMed  Google Scholar 

  46. Lemos VS, Silva DM, Walther T, Alenina N, Bader M, Santos RA (2005) The endothelium-dependent vasodilator effect of the nonpeptide Ang(1–7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. J Cardiovasc Pharmacol 46:274–279

    Article  CAS  PubMed  Google Scholar 

  47. Awad AE, Kandalam V, Chakrabarti S, Wang X, Penninger JM, Davidge ST, Oudit GY, Kassiri Z (2010) Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3Kgamma-dependent manner. Am J Physiol Cell Physiol 298:C679–C692

    Article  CAS  PubMed  Google Scholar 

  48. Guo D, Kassiri Z, Basu R, Chow FL, Kandalam V, Damilano F, Liang W, Izumo S, Hirsch E, Penninger JM et al (2010) Loss of PI3Kgamma enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress. Circ Res 107:1275–1289

    Article  CAS  PubMed  Google Scholar 

  49. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK, Katovich MJ (2007) Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1–7). Am J Physiol Heart Circ Physiol 292:H736–H742

    Article  CAS  PubMed  Google Scholar 

  50. Qi Y, Shenoy V, Wong F, Li H, Afzal A, Mocco J, Sumners C, Raizada MK, Katovich MJ (2011) Lentivirus-mediated overexpression of angiotensin-(1–7) attenuated ischaemia-induced cardiac pathophysiology. Exp Physiol 96:863–874

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Marcus Y, Shefer G, Sasson K, Kohen F, Limor R, Pappo O, Nevo N, Biton I, Bach M, Berkutzki T et al (2013) Angiotensin 1–7 as means to prevent the metabolic syndrome: lessons from the fructose-fed rat model. Diabetes 62:1121–1130

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  52. Gallagher PE, Ferrario CM, Tallant EA (2008) Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol 295:H2373–H2379

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Authors contribution

VBP, AT, TR, SKD, RB, MBG, DAH, and ZK performed experiments, analyzed, and interpreted the data. GYO designed the research and supervised the project. All authors read and approved the final version of the paper.

Funding

We acknowledge the funding support from CIHR, HSF, AI-HS, and GlaxoSmithKline (GSK) to GYO and HL110170 to MBG and GYO. VBP is supported by AI-HS and HSF postdoctoral fellowships. SKD is supported by an AI-HS graduate studentship.

Disclosures

Our research was supported by a research grant from GlaxoSmithKline.

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, University of Alberta, 8440 112 Street NW, Edmonton, AB, T6G 2B7, Canada

    Vaibhav B. Patel, Tharmarajan Ramprasath, Subhash K. Das, Ratnadeep Basu & Gavin Y Oudit

  2. Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Canada

    Vaibhav B. Patel, Abhijit Takawale, Tharmarajan Ramprasath, Subhash K. Das, Ratnadeep Basu, Zamaneh Kassiri & Gavin Y Oudit

  3. Department of Physiology, University of Alberta, Edmonton, Canada

    Abhijit Takawale, Zamaneh Kassiri & Gavin Y Oudit

  4. Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, USA

    Maria B. Grant

  5. GlaxoSmithKline, Stevenage, UK

    David A. Hall

Authors
  1. Vaibhav B. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abhijit Takawale
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tharmarajan Ramprasath
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Subhash K. Das
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ratnadeep Basu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria B. Grant
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. David A. Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zamaneh Kassiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Gavin Y Oudit
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gavin Y Oudit.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(PDF 173 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patel, V.B., Takawale, A., Ramprasath, T. et al. Antagonism of angiotensin 1–7 prevents the therapeutic effects of recombinant human ACE2. J Mol Med 93, 1003–1013 (2015). https://doi.org/10.1007/s00109-015-1285-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00109-015-1285-z

Keywords

Search

Navigation